RPG Life Sciences hosts analyst meet at Anand Rathi G-200 Summit

0 min read | Published on 17 Sept 2026, 05:14 PM |Updated on 17 Sept 2026, 05:14 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

RPG Life Sciences hosts analyst meet on September 22, 2026
Session held at Anand Rathi G-200 Summit 2026 in Mumbai
Format includes group and one-on-one meetings
Disclosure filed under SEBI LODR Regulation 30

*this image is generated using AI for illustrative purposes only.

RPG Life Sciences will host an analyst and institutional investor meet on September 22, 2026. The session is part of the Anand Rathi G-200 Summit 2026, scheduled for 10:00 am onwards in Mumbai.

The company disclosed the engagement pursuant to Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Rajesh Shirambekar, Head-Legal & Company Secretary, signed the disclosure dated September 17, 2026.

Meeting Details

The event will be held in a physical format in Mumbai. RPG Life Sciences will conduct both group and one-on-one sessions with market participants during the summit.

Date	Time	Host/Event	Venue/Mode	Nature
September 22, 2026	10:00 am onwards	Anand Rathi G-200 Summit 2026	Mumbai/Physical	Group/One-on-one

Disclosures

The date is subject to change due to exigencies on the part of the company or the host. Any presentation made during the meet will align with the content available on the company and stock exchange websites.

Historical Stock Returns for RPG Life Sciences

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.12%	+0.44%	+1.52%	+49.07%	+18.24%	+316.59%

What specific strategic initiatives or pipeline updates is RPG Life Sciences expected to highlight to institutional investors at the summit?

How might the outcomes of this investor engagement influence RPG Life Sciences' stock valuation and market sentiment in the short term?

Are there any recent regulatory approvals or clinical trial milestones that will likely serve as key discussion points during the one-on-one sessions?

RPG Life Sciences

View Company Insights

View All News

RPG Life Sciences completes slump sale of APIs business to Raghava

0 min read | Published on 16 Sept 2026, 01:56 AM |Updated on 16 Sept 2026, 01:56 AM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

RPG Life Sciences completes slump sale of APIs and intermediates business
Buyer is Raghava Life Sciences Private Limited
Transaction executed via subsidiary RPG Active Pharma Limited
Transfer effective from September 16, 2026

*this image is generated using AI for illustrative purposes only.

RPG Life Sciences has completed the slump sale of its Active Pharmaceutical Ingredients (APIs) and intermediates business to Raghava Life Sciences Private Limited. The transfer is effective from September 16, 2026.

The transaction was executed through a Business Transfer Agreement (BTA) between Raghava Life Sciences and RPG Active Pharma Limited, a wholly owned subsidiary of RPG Life Sciences. The deal involves the acquisition of the APIs and intermediates businesses as a going concern.

Transaction Details

RPG Life Sciences disclosed the completion to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company had previously informed the exchanges about the execution of the BTA on September 2, 2026.

Detail	Information
Buyer	Raghava Life Sciences Private Limited
Seller	RPG Active Pharma Limited
Business Unit	APIs and intermediates
Effective Date	September 16, 2026
Transaction Type	Slump sale (going concern)